Elnecave Regina Helena, Kopacek Cristiane, Rigatto Marilia, Keller Brenner Juliana, Sisson de Castro José Augusto
Hospital de Clinicas de Porto Alegre, Endocrinology Section, Porto Alegre, Brasil.
J Pediatr Endocrinol Metab. 2008 Dec;21(12):1155-62. doi: 10.1515/jpem.2008.21.12.1155.
To verify possible associations among glucocorticoid doses, use of dexamethasone, and bone mineral density (BMD), measured by dual X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), in female children with congenital adrenal hyperplasia due to CYP21 deficiency (CAH-CYP21). Classical CAH-CYP21 in females allows the study of the effects of hyperandrogenism and chronic glucocorticoid exposure.
Cross-sectional observational study.
Sixteen girls (4-19 years) with CAH-CYP21 and 32 age-matched control girls.
BMD was the main outcome measure assessed by total body and lumbar spine L1-L4 DXA (DXAtot and DXAIs), lumbar spine L1-L4 bone mineral apparent density (BMAD) and spinal L1-L4 QCT of trabecular (QCTtrab) and cortical (QCTcort) bone. The glucocorticoid dose used by patients with CAH-CYP21 was expressed as hydrocortisone equivalents/m2.
Mean BMD in both groups was similar by any method. In patients, BMD decreased with the increasing mean dose of glucocorticoid, seen in QCTcort (r = -0.55; p = 0.03) and QCTtrab (r = -0.52; p = 0.04). There was also a negative correlation between cumulative glucocorticoid dose and BMD in QCTcort (beta = -0.0016; p = 0.005) and QCTtrab (beta = -0.0009; p = 0.03).
The dose of glucocorticoid used in the treatment of girls with CAH-CYP21 correlated negatively with BMD, and dexamethasone was not selectively harmful.
验证因CYP21缺乏所致先天性肾上腺皮质增生症(CAH-CYP21)女童中,通过双能X线吸收测定法(DXA)和定量计算机断层扫描(QCT)测量的糖皮质激素剂量、地塞米松的使用与骨密度(BMD)之间可能存在的关联。女性经典型CAH-CYP21有助于研究高雄激素血症和慢性糖皮质激素暴露的影响。
横断面观察性研究。
16名患有CAH-CYP21的女孩(4 - 19岁)和32名年龄匹配的对照女孩。
骨密度是主要结局指标,通过全身和腰椎L1 - L4的DXA(DXAtot和DXAIs)、腰椎L1 - L4骨矿物质表观密度(BMAD)以及腰椎L1 - L4小梁骨(QCTtrab)和皮质骨(QCTcort)的QCT进行评估。CAH-CYP21患者使用的糖皮质激素剂量以氢化可的松等效剂量/m²表示。
两组的平均骨密度通过任何方法测量均相似。在患者中,骨密度随着糖皮质激素平均剂量的增加而降低,在QCTcort(r = -0.55;p = 0.03)和QCTtrab(r = -0.52;p = 0.04)中可见。QCTcort(β = -0.0016;p = 0.005)和QCTtrab(β = -0.0009;p = 0.03)中累积糖皮质激素剂量与骨密度之间也存在负相关。
用于治疗CAH-CYP21女童的糖皮质激素剂量与骨密度呈负相关,且地塞米松并无选择性危害。